DeepMed Research

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Golcadomide

Generic Name: Golcadomide

Drug Type: Small Molecule

Chemical Formula: C_₂₈H_₃₀FN_₅O_₅

CAS Number: 2379572-34-4

Unique Ingredient Identifier: 29HLR8Z5BR

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma (GOLSEEK-4)

Phase 3

Not yet recruiting

Posted: 2025/04/04

Sponsor:Celgene

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

Phase 2

Recruiting

Posted: 2025/02/19

Sponsor:Mayo Clinic

Golcadomide and Nivolumab in Patients with Non-Hodgkin Lymphoma with Refractory Disease After Chimeric Antigen T-cell Therapy

Phase 1

Not yet recruiting

Posted: 2025/01/10

Sponsor:

Natalie Galanina

Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

Phase 1

Recruiting

Posted: 2024/08/02

Sponsor:Celgene

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

Phase 2

Recruiting

Posted: 2024/05/22

Sponsor:Celgene

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

B-Cell Lymphoma Pipeline Expands with 300+ Therapies in Development for 2025

2 months ago

DelveInsight's latest report reveals a robust B-cell lymphoma pipeline with over 295 companies developing 300+ therapies, highlighting significant industry investment in this area.

T-Cell Lymphoma Pipeline Shows Promise with Novel Therapies and Regulatory Support

7 months ago

The T-Cell Lymphoma drug pipeline is advancing with key players like Eisai, Takeda, and Rhizen Pharmaceuticals developing innovative therapies.

Golcadomide Plus R-CHOP Shows Promise in Aggressive B-Cell Lymphoma

9 months ago

Golcadomide combined with R-CHOP demonstrates a manageable safety profile and promising antitumor activity in previously untreated aggressive B-cell lymphoma.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy